Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission (Q41200444)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 March 2015

Language	Label	Description	Also known as
English	Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission	scientific article published on 19 March 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Andrew C. Harris

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

John M Magenau

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Thomas Braun

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Pavan Reddy

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Attaphol Pawarode

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Shin Mineishi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sung Choi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

John Levine

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Yumeng Li

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Gregory Yanik

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Carrie Kitko

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Tracey Churay

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

David Frame

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Mary Mansour Riwes

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Dale Bixby

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Daniel R Couriel

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Steven C Goldstein

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

19 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

94

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1033-1041

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Optimal induction and post-remission therapy for AML in first remission

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Acute myeloid leukemia in first remission: to choose transplantation or not?

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Defining the intensity of conditioning regimens: working definitions

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Busulfan in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2349-4

21 January 2018

Identifiers

10.1007/S00277-015-2349-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25784222%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41200444&oldid=2102583384"